Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis
Endocrine Journal · 2026
DOI: 10.1507/endocrj.ej25-0539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2026. Verfasst von Sueyoshi Moritani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Phenylurea Compounds, Quinolines, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan.
- Department of Pharmacy, Omi Medical Center, Shiga 525-8585, Japan.
Zitieren
APA
Moritani, S., Takenobu, M., Yasunaga, M., Fujii, T., Moritani, M., Bando, R., Oda, S., Harada, Y., & Kitano, H. (2026). Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis. Endocrine Journal. https://doi.org/10.1507/endocrj.ej25-0539
Vancouver
Moritani S, Takenobu M, Yasunaga M, Fujii T, Moritani M, Bando R, et al. Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis. Endocrine Journal. 2026. doi:10.1507/endocrj.ej25-0539
BibTeX
@article{Moritani2026,
author = {Moritani, Sueyoshi and Takenobu, Masao and Yasunaga, Masakazu and Fujii, Taihei and Moritani, Mako and Bando, Rie and Oda, Shoko and Harada, Yuki and Kitano, Hiroya},
title = {Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis},
journal = {Endocrine Journal},
year = {2026},
doi = {10.1507/endocrj.ej25-0539}
}
EUVIMED